ClinVar Miner

Submissions for variant NM_002878.3(RAD51D):c.394G>A (p.Val132Ile) (rs201141245)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000164547 SCV000215203 likely benign Hereditary cancer-predisposing syndrome 2017-07-07 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Other strong data supporting benign classification
Color RCV000164547 SCV000910748 likely benign Hereditary cancer-predisposing syndrome 2016-02-22 criteria provided, single submitter clinical testing
Counsyl RCV000458927 SCV000784995 uncertain significance Breast-ovarian cancer, familial 4 2017-03-06 criteria provided, single submitter clinical testing
GeneDx RCV000588322 SCV000292678 uncertain significance not provided 2018-04-19 criteria provided, single submitter clinical testing This variant is denoted RAD51D c.394G>A at the cDNA level, p.Val132Ile (V132I) at the protein level, and results in the change of a Valine to an Isoleucine (GTC>ATC). This variant has been observed in at least two individuals with a personal and/or family history of breast cancer and at least two individuals with epithelial ovarian cancer (Thompson 2013, Song 2015, Kraus 2017). RAD51D Val132Ile was observed at an allele frequency of 0.03% (6/24,020) in individuals of African ancestry in large population cohorts (Lek 2016). This variant is located in the RAD51C binding domain (Miller 2004). In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether RAD51D Val132Ile is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
GeneKor MSA RCV000164547 SCV000822177 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000588322 SCV000698100 uncertain significance not provided 2017-04-20 criteria provided, single submitter clinical testing Variant summary: The c.394G>A (p.Val132Ile) in RAD51D gene is a missense change that involves a non-conserved nucleotide. Although the variant is located within the ATP binding site of conserved domain Rad51_DMC1_radA, 4/5 in silico tools predict benign outcome. The variant is present in the large control population dataset of ExAC and gnomAD at a similar frequencies of 0.00007 (9/121398 and 17/277162 chrs tested, respectively), predominantly in individuals of African descent (0.0002884; 3/10404 and 6/24020 chrs tested) which exceeds the maximal expected frequency of a pathogenic allele (0.00012) in this gene. The variant has been reported in at least 1 sporadic brC case (Kraus, 2017) and 2 BrC families without strong evidence for causality (Thompson, 2013; Song, 2015). Lastly, several reputable databases/clinical laboratories cite the variant with classification of VUS but favoring the benign nature of this change. Taking all line of evidence into consideration, the variant was conservatively classified as VUS-Possibly Benign.
Invitae RCV000458927 SCV000551340 uncertain significance Breast-ovarian cancer, familial 4 2018-12-24 criteria provided, single submitter clinical testing This sequence change replaces valine with isoleucine at codon 132 of the RAD51D protein (p.Val132Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs201141245, ExAC 0.03%), and has an allele count higher than expected for a pathogenic variant (PMID: 28166811). This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 27616075, 23372765, 26261251). ClinVar contains an entry for this variant (Variation ID: 185178). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
University of Washington Department of Laboratory Medicine,University of Washington RCV000458927 SCV000886447 likely benign Breast-ovarian cancer, familial 4 2018-05-09 criteria provided, single submitter research The RAD51D variant designated as NM_002878.3:c.394G>A (p.Val132Ile) is classified as likely benign. This variant is listed in ClinVar (Variation ID: 141739) and has been classified as likely benign by another laboratory. Computer software programs (SIFT, Polyphen-2, Align-GVGD) all predict that this variant is likely to be tolerated. In one observed family, this variant was not detected in an affected relativer’s ovarian tumor, which indicates that it is unlikely to be the cause of her ovarian cancer. Bayesian analysis integrating all of this data (Tavtigian et al, 2018, PMID:29300386) gives about a 3% probability of pathogenicity, which is consistent with a classification of likely benign. This variant is not predicted to alter RAD51D function or modify cancer risk. A modest (less than 2 fold) increase in cancer risk due to this variant cannot be entirely excluded. This analysis was performed in conjunction with the family studies project as part of the University of Washington Find My Variant Study.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.